NCT05679518 Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches
| NCT ID | NCT05679518 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Advanced or Metastatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 284 participants |
| Start Date | 2023-12-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 284 participants in total. It began in 2023-12-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study aims to conduct a randomized controlled trial to assess the effect of CALM intervention and ConquerFear intervention on fear of cancer progression among Chinese patients diagnosed with advanced cancer.
Eligibility Criteria
Inclusion Criteria: * Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with advanced or metastatic (i.e. stage III or IV) cancer * are the age of 18 years or above Exclusion Criteria: * Patients with major communication difficulties * are being unwilling or unable to commit 6 psychotherapy sessions
Contact & Investigator
Wendy Wing Tak Lam, PhD
PRINCIPAL INVESTIGATOR
School of Public Health, The University of Hong Kong
Frequently Asked Questions
Who can join the NCT05679518 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced or Metastatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05679518 currently recruiting?
Yes, NCT05679518 is actively recruiting participants. Contact the research team at dwlng@hku.hk for enrollment information.
Where is the NCT05679518 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong.
Who is sponsoring the NCT05679518 clinical trial?
NCT05679518 is sponsored by The University of Hong Kong. The principal investigator is Wendy Wing Tak Lam, PhD at School of Public Health, The University of Hong Kong. The trial plans to enroll 284 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.